Medtech's Structural Reset: Five Trends Defining the Industry in 2026

Executive Summary

The medical technology industry is entering a period of accelerated transformation, driven by structural changes in pricing, care delivery, supply chains, clinical pathways, and enabling technologies. Drawing on Clarivate's proprietary data and expert analysis, this article examines five trends that will shape competitive dynamics in 2026 and beyond: Mainland China's volume-based procurement expansion, the shift of procedures to outpatient settings, supply chain restructuring, the ripple effects of GLP-1 therapies, and the rise of platform-based competition. These forces are not isolated; they are redefining how medtech companies create value, compete, and plan for long-term growth.

Introduction

For years, the medical technology sector operated under stable assumptions: pricing power in key markets, hospital-centric procedure growth, globally efficient supply chains, and product-level differentiation. By 2026, those assumptions are being upended. A convergence of policy, technology, and clinical innovation is forcing executives to rethink strategies across portfolios, manufacturing footprints, and commercial models. The result is a structural reset in which competitive advantage depends on anticipating systemic shifts rather than merely iterating on devices.

Market Context

The global medtech market is navigating heightened price sensitivity, shifting site-of-care patterns, and geopolitical supply disruptions. Meanwhile, the rapid adoption of GLP-1 receptor agonists is altering patient pathways for metabolic conditions, and digital technologies are becoming integral to surgical platforms. Understanding these dynamics is essential for stakeholders ranging from device manufacturers to investors, because the industry is moving toward a new equilibrium where scale alone is no longer sufficient.

Main Analysis

1. Mainland China's VBP Expansion Redefines Global Pricing and Competition

Mainland China's national volume-based procurement (VBP) program has evolved from an access-expansion mechanism into a core market-shaping tool. New rules introduce more sophisticated anchor-price logic, deeper price compression, and allocation systems favoring domestic manufacturers. Multinationals now face pressure not only in China but in markets where price expectations are influenced by Chinese benchmarks. Strategic implications include portfolio rationalization, local partnerships, and a greater emphasis on innovation volume. The program is accelerating domestic innovation and reshaping portfolio strategy. As VBP becomes a global reference point, medtech companies must treat pricing policy as a strategic input, not merely a compliance issue.

2. Outpatient and Ambulatory Surgery Centers Become Central to Procedure Strategy

The migration of procedures from hospitals to outpatient settings accelerates, reinforced by the U.S. Centers for Medicare & Medicaid Services' 2026 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System Final Rule. Higher-acuity procedures such as cardiac ablation are moving to lower-cost sites. Medtech companies must adapt commercial models, develop site-specific value propositions, and design products for the unique operational realities of ambulatory surgery centers. This affects everything from capital equipment sales to single-use device packaging. The trend builds on long-running patterns in orthopedics and general surgery, and it is fundamentally altering procedure demand forecasts.

3. Supply Chain Pressures Reshape Manufacturing Strategy

Tariffs, geopolitical tensions, and material cost volatility are prompting a strategic re-evaluation of production footprints. Companies are diversifying sourcing, adopting multi-region manufacturing, and leveraging scale to buffer against disruptions. Supply chain resilience is now a distinct competitive advantage, affecting cost structures and time-to-market. Larger manufacturers are using integration and technology investment to create flexible production networks. This trend is likely to accelerate as companies seek flexibility in an unpredictable global environment. Cost structures, supplier concentration, and manufacturing geography will increasingly influence competitive advantage alongside product performance.

4. GLP-1 Therapies Alter Patient Behavior and Care Pathways

The rise of GLP-1 receptor agonists is shifting how metabolic disease is managed, with downstream effects on bariatric surgery, diabetes care, sleep apnea, and cardiovascular monitoring. While bariatric surgery remains the most effective intervention for substantial weight loss, demand is being reallocated. Medtech companies must monitor volume shifts, adjust forecasting, and explore adjacent opportunities created by new weight-management paradigms. The impact is not uniform; certain bariatric procedures are experiencing sharper volume pressure than others. The broader implication is that clinical pathway shifts have become a key variable in portfolio planning.

5. Enabling Technologies Drive Platform-Based Competition

Robotics, imaging, navigation, and digital workflow software are no longer adjuncts but are converging into integrated platforms that anchor entire service lines. Companies investing in open-platform architectures can strengthen customer relationships and unlock data-driven value propositions. Competition is shifting from individual devices to ecosystems, with implications for R&D investment, M&A strategy, and customer engagement. These platforms support clinical planning, surgical execution, and postoperative care, creating new barriers to entry and new opportunities for cross-selling. Emerging open-platform systems are expanding flexibility and generating new competitive dynamics.

Business Impact

• Corporate Strategy: Portfolio decisions must account for pricing pressures in key geographies and emerging opportunities in outpatient and platform-based offerings.
• Commercial Competitiveness: Value propositions must be tailored to diverse site-of-service economics and data-enabled outcomes.
• Operations: Supply chain resilience becomes integral to financial performance; multi-region manufacturing and supplier diversification are priorities.
• Investment: Capital allocation will favor companies with platform assets, supply chain agility, and exposure to high-growth care settings.
• Innovation: R&D should align with enabling technologies and clinical pathways transformed by GLP-1 adoption.

Executive Insights

Leadership must move beyond product-centric thinking. The most successful medtech companies will treat pricing policy as a strategic input, not a compliance issue. They will design commercial teams around outpatient settings. They will embed supply chain risk in capital planning. And they will pursue partnerships that build platform ecosystems rather than simple product lines. The GLP-1 effect requires scenario planning across multiple franchises, and VBP demands a nuanced view of China—both as a market with tremendous scale and as a source of pricing signals that may propagate globally. Executives who develop these capabilities will be better positioned to navigate the industry's complexity and capture value.

Future Outlook

Over the next three to ten years, these trends will intensify. China's domestic medtech sector will become more innovative and export-oriented. Outpatient migration will continue, expanding the ambulatory surgery market. Supply chains will become more regionalized and digitized. Interactions between GLP-1s and medtech will evolve as weight management becomes part of chronic care bundles. And platform technologies will drive consolidation, with a few ecosystems dominating key service lines. Medtech companies that adapt early will gain durable advantages. Those that wait risk being locked out of growth segments and burdened by legacy cost structures.

Conclusion

The medical technology industry is undergoing a structural reset. The five trends outlined here reveal a sector where competitive advantage is earned not merely through product innovation but through strategic mastery of pricing systems, care delivery evolution, supply chain resilience, clinical pathway shifts, and technology platforms. For executives, investors, and policymakers, understanding these forces is essential to navigating the next era of global medtech.

Source: This article is based on Clarivate's "Medtech Trends to Watch in 2026" report, available at https://clarivate.com/life-sciences-healthcare/blog/5-medtech-trends-to-watch-in-2026.